News
Ozempic-Maker CEO Ousted Over Pharma Company’s Rocky Market Downturn
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the company. The Danish pharmaceutical giant announced Friday that, amidst a recent downturn in the company’s stock,
Danish pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping ...
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
GlobalData on MSN2d
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapiesNovo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will ...
Despite Ozempic being the most recognisable brand name, as far as the people prescribing it are concerned weight loss is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback